Jorge Romaguera
6PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Mar 02, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.Tamer Khashab, Fredrick Hagemeister, Jorge E Romaguera
|Sep 04, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.Preetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang
|May 23, 2018
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).Preetesh Jain, Jorge Romaguera, Samer A Srour
|May 10, 2018
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.Jorge E Romaguera, Hun J Lee, Rohinton Tarapore
|May 04, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.Jorge E Romaguera, Michael Wang, Lei Feng
|Mar 13, 2018
A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma.Hun J Lee, Maria Badillo, Jorge Romaguera
Pageof 1
